MDxHealth to Present at the 2013 BIO CEO & Investor Conference
(Thomson Reuters ONE) -
IRVINE, CA, and LIEGE, BELGIUM - February 4, 2013 - MDxHealth SA (NYSE Euronext:
MDXH), a leading molecular diagnostic company that develops and commercializes
epigenetic tests to support cancer diagnosis and treatment, today announced that
Dr. Jan Groen , the Company's Chief Executive Officer, will present at the
15(th) Annual BIO CEO & Investor Conference on Monday, February 11th 2013 at
3.00 pm Eastern Time at the Waldorf-Astoria in New York, NY.
About the BIO CEO & Investors Conference
The Annual BIO CEO & Investor Conference is the largest investor conference
focused on established and emerging publicly traded biotech companies. This
year's conference will feature corporate presentations from more than 130
leading biotechnology and pharmaceutical companies. The presenting companies
consist of a selection of mid- to large-cap established public companies from
around the globe, who typically have a clinical stage program centered around
therapeutics, molecular diagnostics, or a platform technology, as well as an
upcoming clinical, regulatory, or corporate catalyst. More information on the
conference can be found at www.bio.org.
About MDxHealth
MDxHealth is a molecular diagnostics company that develops and commercializes
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. The company's first commercial product, the ConfirmMDx for Prostate
Cancer test, has been shown to help distinguish patients who have a true-
negative biopsy from those who may have occult cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer diagnosis and
treatment information. The company has a proprietary platform and a strong
epigenetic product pipeline focused on the development of products for brain and
lung cancers. The company is based in Irvine, California with a European
headquarters in Liege, Belgium. For more information visit MDxHealth website at
www.mdxhealth.com.
Contacts
Company :
Dr Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info(at)mdxhealth.com
Media :
Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955
US: +1 646 378 2952
Cell: +44 7968 022075
msinclair(at)halsin.com
Investors :
Seth Lewis
The Trout Group
US : + 1 646 378 2952
slewis(at)troutgroup.com
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation.
BIO CEO ENG:
http://hugin.info/137314/R/1675036/545586.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MdxHealth via Thomson Reuters ONE
[HUG#1675036]
Unternehmensinformation / Kurzprofil:
Datum: 04.02.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 225698
Anzahl Zeichen: 4236
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 159 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MDxHealth to Present at the 2013 BIO CEO & Investor Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
MdxHealth (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
